File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Complement activation by PEGylated single-walled carbon nanotubes is independent of C1q and alternative pathway turnover

TitleComplement activation by PEGylated single-walled carbon nanotubes is independent of C1q and alternative pathway turnover
Authors
KeywordsBiomaterials
C4
Carbon nanotubes
Complement system
Drug delivery system
Nanomedicine
SC5b-9
Issue Date2008
Citation
Molecular Immunology, 2008, v. 45, n. 14, p. 3797-3803 How to Cite?
AbstractWe have investigated the interaction between long circulating poly(ethylene glycol)-stabilized single-walled carbon nanotubes (SWNTs) and the complement system. Aminopoly(ethylene glycol)5000-distearoylphosphatidylethanolamine (aminoPEG5000-DSPE) and methoxyPEG5000-DSPE coated as-grown HIPco SWNTs activated complement in undiluted normal human serum as reflected in significant rises in C4d and SC5b-9 levels, but not the alternative pathway split-product Bb, thus indicating activation exclusively through C4 cleavage. Studies in C2-depleted serum confirmed that PEGylated nanotube-mediated elevation of SC5b-9 was C4b2a convertase-dependent. With the aid of monoclonal antibodies against C1s and human serum depleted from C1q, nanotube-mediated complement activation in C1q-depleted serum was also shown to be independent of classical pathway. Nanotube-mediated C4d elevation in C1q-depleted serum, however, was inhibited by N-acetylglucosamine, Futhan (a broad-spectrum serine protease inhibitor capable of preventing complement activation through all three pathways) and anti-MASP-2 antibodies; this strongly suggests a role for activation of MASP-2 in subsequent C4 cleavage and assembly of C4b2a covertases. Intravenous injection of PEGylated nanotubes in some rats was associated with a significant rise in plasma thromboxane B2 levels, indicative of in vivo nanotube-mediated complement activation. The clinical implications of these observations are discussed. © 2008 Elsevier Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/334178
ISSN
2021 Impact Factor: 4.174
2020 SCImago Journal Rankings: 1.291
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorHamad, Islam-
dc.contributor.authorChristy Hunter, A.-
dc.contributor.authorRutt, Kenneth J.-
dc.contributor.authorLiu, Zhuang-
dc.contributor.authorDai, Hongjie-
dc.contributor.authorMoein Moghimi, S.-
dc.date.accessioned2023-10-20T06:46:17Z-
dc.date.available2023-10-20T06:46:17Z-
dc.date.issued2008-
dc.identifier.citationMolecular Immunology, 2008, v. 45, n. 14, p. 3797-3803-
dc.identifier.issn0161-5890-
dc.identifier.urihttp://hdl.handle.net/10722/334178-
dc.description.abstractWe have investigated the interaction between long circulating poly(ethylene glycol)-stabilized single-walled carbon nanotubes (SWNTs) and the complement system. Aminopoly(ethylene glycol)5000-distearoylphosphatidylethanolamine (aminoPEG5000-DSPE) and methoxyPEG5000-DSPE coated as-grown HIPco SWNTs activated complement in undiluted normal human serum as reflected in significant rises in C4d and SC5b-9 levels, but not the alternative pathway split-product Bb, thus indicating activation exclusively through C4 cleavage. Studies in C2-depleted serum confirmed that PEGylated nanotube-mediated elevation of SC5b-9 was C4b2a convertase-dependent. With the aid of monoclonal antibodies against C1s and human serum depleted from C1q, nanotube-mediated complement activation in C1q-depleted serum was also shown to be independent of classical pathway. Nanotube-mediated C4d elevation in C1q-depleted serum, however, was inhibited by N-acetylglucosamine, Futhan (a broad-spectrum serine protease inhibitor capable of preventing complement activation through all three pathways) and anti-MASP-2 antibodies; this strongly suggests a role for activation of MASP-2 in subsequent C4 cleavage and assembly of C4b2a covertases. Intravenous injection of PEGylated nanotubes in some rats was associated with a significant rise in plasma thromboxane B2 levels, indicative of in vivo nanotube-mediated complement activation. The clinical implications of these observations are discussed. © 2008 Elsevier Ltd. All rights reserved.-
dc.languageeng-
dc.relation.ispartofMolecular Immunology-
dc.subjectBiomaterials-
dc.subjectC4-
dc.subjectCarbon nanotubes-
dc.subjectComplement system-
dc.subjectDrug delivery system-
dc.subjectNanomedicine-
dc.subjectSC5b-9-
dc.titleComplement activation by PEGylated single-walled carbon nanotubes is independent of C1q and alternative pathway turnover-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.molimm.2008.05.020-
dc.identifier.pmid18602161-
dc.identifier.scopuseid_2-s2.0-48049083322-
dc.identifier.volume45-
dc.identifier.issue14-
dc.identifier.spage3797-
dc.identifier.epage3803-
dc.identifier.isiWOS:000259473900013-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats